Neuroscience R&D newsroom

Bill Martin is the Global Focus Area Head, Neuroscience, at Johnson & Johnson Innovative Medicine and a member of the company’s Group Operating Committee. He leads a dedicated team focused on the discovery and development of a precision neuroscience pipeline of transformative treatments for individuals grappling with serious neuropsychiatric and neurodegenerative disorders. Building on Johnson & Johnson’s 60-year legacy in neuroscience, Bill’s team is driving a differentiated portfolio of new and innovative therapies, each targeting a subpopulation of patients.

Peter Fang is the Worldwide Vice President, Neuroscience Global Commercial Strategy Organization for the Janssen Pharmaceutical Companies of Johnson & Johnson. Working closely with Janssen Research & Development, he is responsible for developing and driving commercial strategies for the Neuroscience portfolio and pipeline within neuropsychiatric, neurodegenerative and autoantibody-driven diseases of the nervous system. Peter oversees Strategic Marketing, Market Access, Medical Affairs and Strategic Analytics teams that support the Global Neuroscience business.

Fiona Elwood, Ph.D., has extensive experience in neuroscience and neurodegenerative research and development, a passion for bringing relief to patients and their caregivers, and dedication to scientific excellence and exceptional teamwork. She brings deep expertise in molecular mechanisms of neurodegeneration, including in tau biology, and the use of human cell models and advanced screening approaches to support novel target identification and validation.

Wayne Drevets, M.D. is Stronghold Leader, Neuropsychiatry Disease Area for Neuroscience, where he leads a cross-functional team in the development of Janssen’s industry-leading portfolio of novel therapeutics in mood and psychotic disorders. Wayne also oversees the strategy, conception, and execution of a program he built at Janssen for developing novel treatments for major depressive disorder, bipolar disorder, and schizophrenia from discovery through late-development phases.